Aram Modrek, MD
Enriched profileRadiation oncologist, USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC; Assistant Professor of Radiation Oncology · Keck School of Medicine of USC
Aram Modrek is Radiation oncologist, USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC; Assistant Professor of Radiation Oncology at Keck School of Medicine of USC. OpenAlex indexes 62 publications with 1,228 citations (h-index 15).
Data verified 27 Oct 2026
Overview
Updated 2 Nov 2026
Aram Sandaldjian Modrek, MD, PHD, is Radiation oncologist, USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC at Keck School of Medicine of USC (Keck Medicine of USC). The public record shows 62 publications with 1,228 citations (h-index 15), centered on Glioma Diagnosis and Treatment, Cancer, Hypoxia, and Metabolism, Cancer Cells and Metastasis. It also documents industry payments reported by 1 companies, 1 NIH-funded awards (2023–2026).
- Most recent indexed publication: 2026 · Cancers
- Top research focus: Glioma Diagnosis and Treatment
- Open Payments reporting from 1 companies
Generated from the cited public record · current as of 2 Nov 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 18.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
We didn't find any investigator roles for this person on ClinicalTrials.gov. Why? →
Industry payments
Updated 2 Nov 2026
1 company reported payments to CMS in program years 2024–2025. These are public disclosures, not judgments. The latest:
- Novocure Inc.Program year20251 payment
- Novocure Inc.Program year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
100%Corticosteroid100%Dexamethasone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 2 Nov 2026
1 NIH research award on record, funded 2023–2026 per NIH RePORTER. The latest:
- Epigenetic alterations after DNA damage repair drive treatment resistance in glioblastoma
University of Southern California
FY2026$142,007K08CA263302 - Epigenetic alterations after DNA damage repair drive treatment resistance in glioblastoma
University of Southern California
FY2025$142,007K08CA263302 - Epigenetic alterations after DNA damage repair drive treatment resistance in glioblastoma
University of Southern California
FY2024$142,007K08CA263302
Congress activity
Updated 2 Nov 2026
11 congress contributions (2013–2026) across AACR, ASTRO per OpenAlex. The most recent:
- Abstract 7376: HMGB2-mediated radioresistance of glioblastoma stem cells
AACR Annual Meeting
AACR2026Co-author - Abstract 2819: Genome-wide CRISPR screen identifies NANP as a radio-sensitizing target of GBM by regulating NF-κB pathway
AACR Annual Meeting
AACR2023Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 2 Nov 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Persistent chromatin alterations and gene expression reprogramming follow widespread DNA damage in glioblastoma.
Nature communications
Article2026 - NANP targeting radiosensitizes glioblastoma through TNFR1 sialylation-driven mesenchymal shift.
Nature communications
Article2026
Most-cited works
by citation count (OpenAlex)- 01Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsReview229 citations2019
- 02Multiple modes of PRC2 inhibition elicit global chromatin alterations in H3K27M pediatric gliomaArticle191 citations2018
- 03
- 04Brain stem cells as the cell of origin in gliomaArticle91 citations2014
- 05Targeting Tumor Suppressor Networks for Cancer TherapeuticsArticle82 citations2014
Network
Updated 2 Nov 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 2 Nov 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/aram-modrek-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
med.nyu.edu/faculty/aram-s-modrek
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.nyu.edu ↗ - Other
keckmedicine.org/provider/aram-sandaldjian-modrek
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →keckmedicine.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 2 Nov 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
New York University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.nyu.edu ↗ - PhD
New York University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.nyu.edu ↗
Editorial & leadership roles
journal and society appointments- Member
Society for Neuro-Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ent.keckmedicine.org ↗ - Member
American Association for Cancer Research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ent.keckmedicine.org ↗ - Member
American Society for Radiation Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ent.keckmedicine.org ↗ - Member
American Brain Tumor Association
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ent.keckmedicine.org ↗ - Member
Radiological Society of North America
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ent.keckmedicine.org ↗
Awards & honors
honors on the public record- V Foundation Scholar Award ($600,000)
glioblastoma treatment escape research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncodaily.com ↗
Secondary affiliations
appointments beyond the home institution- New York University Grossman School of Medicine
Research Assistant Professor, Department of Radiation Oncology (past, per NYU profile)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →med.nyu.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Norah Terrault, MD
Keck School of Medicine of USC
John Ringman, MD
Keck School of Medicine of USC
Leslie Saxon, MD
Keck School of Medicine of USC
William Stohl, MD
Keck School of Medicine of USC
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
Timothy Cloughesy, MD
Ronald Reagan UCLA Medical Center